

Impact of National Health Policies and Antimicrobial Stewardship Programs on Antibiotic Utilization and Resistance Patterns in Healthcare Facilities

Hafiz Usama Khalil

Lecturer School of pharmacy Multan University of science and technology (MUST)
Multan

usamakhalil194@gmail.com

Talha

University of Makran

talha@uomp.edu.pk

Author Details

Keywords: Antimicrobial Resistance, Antimicrobial Stewardship Programs, National Health Policies, Pathogen Susceptibility, Regulatory Circumvention, One Health.

Received on 01 March 2026

Accepted on 15 March 2026

Published on 25 March 2026

Corresponding E-mail & Author*:

Hafiz Usama Khalil

Lecturer School of pharmacy
Multan University of science and
technology (MUST) Multan

usamakhalil194@gmail.com

Abstract

The global escalation of antimicrobial resistance (AMR) is a profound public health threat linked to millions of deaths and devastating macroeconomic consequences. The primary biological driver of this crisis is selective pressure from inappropriate antibiotic utilization across human and agricultural sectors. To combat AMR, healthcare systems deploy multi-layered intervention models integrating macro-level national health policies with micro-level institutional Antimicrobial Stewardship Programs (ASPs). This review examines the quantitative impacts, structural designs, and administrative challenges of these initiatives. Evidence indicates that higher national policy governance scores are strongly associated with improved antibiotic use trends, though implementation remains severely underfunded in low- and middle-income countries. Locally, ASPs utilizing front-end restrictions and back-end prospective audits consistently reduce total antibiotic consumption by up to 28% and lower the use of high-risk

broad-spectrum agents. Furthermore, diagnostic stewardship and selective laboratory reporting successfully steer clinicians toward rational prescribing. However, the ecological consequences on pathogen susceptibility are highly variable. While targeted restrictions have engineered substantial susceptibility rebounds in *Klebsiella pneumoniae*, *Acinetobacter baumannii*, and *Staphylococcus aureus*, they can also cause collateral selective shifts that increase resistance in alternative pathogen-drug pairs. Financially, ASPs achieve massive direct medication cost savings, yet top-down mandatory policy targets risk creating unintended behaviors. Clinicians facing rigid indicators may engage in regulatory circumvention, such as shifting broad-spectrum procurement out-of-pocket to retail pharmacies, which artificially deflates hospital metrics while burdening patients. Mitigating these systemic barriers requires balancing administrative mandates with supportive, face-to-face clinical modeling and comprehensive socio-ecological collective action.

Keywords: Antimicrobial Resistance, Antimicrobial Stewardship Programs, National Health Policies, Pathogen Susceptibility, Regulatory Circumvention, One Health.

1. Introduction

The global spread of antimicrobial resistance (AMR) represents one of the most critical public health threats of the twenty-first century, with a disease burden estimated to be at least as high as that of HIV and malaria combined (Global Research on Antimicrobial Resistance, 2019). In 2019, global estimates indicated that AMR directly caused or was associated with 4.95 million deaths, a figure that remains high with recent projections recording 4.71 million associated deaths in 2021 (Antimicrobial Resistance Collaborators, 2022). Historically, AMR claimed at least 700,000 lives annually, including 230,000 from multidrug-resistant (MDR) tuberculosis (World Health Organization, 2018). Left unmitigated, the epidemiological trajectory of AMR is projected to result in 10 million deaths annually by 2050, alongside a staggering global economic loss of up to 100 trillion in gross domestic product (GDP) contractions and cumulative welfare losses (World Bank, 2017).

The fundamental biological mechanism driving this crisis is the selective pressure exerted by the inappropriate and indiscriminate utilization of antimicrobial agents (Bell et al., 2014; Holmes et al., 2016). Clinical audits indicate that up to 30% of prescribed antibiotics are completely unnecessary or inappropriate (O'Connor et al., 2016). Common factors accelerating this pressure include the administration of broad-spectrum agents for viral or non-bacterial etiologies, excessive treatment durations, and patient-level misuse, such as self-medication and the hoarding of leftover drugs. Indeed, surveys reveal that 53.7% of patients admit to having leftover antibiotics, with 77.0% of those individuals saving them for future unprescribed use and 4.6% distributing them to others (Grigoryan et al., 2008).

Within the hospital ecosystem, intensive care units (ICUs) represent hotspots of selection, contributing to a disproportionately high rate of broad-spectrum prescriptions that decimate patient microbiotas, eliminate natural colonization resistance, and foster the transmission of highly resistant pathogens (Kaki et al., 2012). Chief among these threats are the ESCAPE pathogens (*Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Enterobacter* species, recently amended to include *Clostridioides difficile*), which are frequently associated with severe, hard-to-treat nosocomial infections. To address this challenge, health authorities have designed multi-layered intervention models, integrating macro-level national health policies with micro-level institutional Antimicrobial Stewardship Programs (ASPs) (Nathwani et al., 2019).

2. National Health Policies and Global Governance Frameworks

At the international level, global governance is guided by the World Health Organization's (WHO) second edition of the Global Action Plan on Antimicrobial Resistance (GAP-AMR), which outlines an adaptive, ten-year strategic framework through 2036 (Jonas et al., 2017). The plan targets a 10% reduction in global bacterial AMR-associated human deaths by 2030, anchored in a comprehensive "One Health" approach that addresses resistance drivers across human health, veterinary sectors, agriculture, and environmental waste (World Health Organization, 2025). The integration of veterinary sectors is essential, as antibiotic consumption in food-producing animals could increase by 29.5% from 2019 levels to reach 142,481 tonnes by 2040, although global animal utilization declined by 5% between 2020 and 2022, and 71% of countries banned the use of antimicrobials as growth promoters in animal husbandry (Mulchandani et al., 2023). Projections show that a 30% reduction in animal antibiotic use within five years could boost global GDP by 120 billion, while the World Organisation for Animal Health (WOAH) is actively developing a

veterinary equivalent of the WHO AWaRe classification to close livestock surveillance gaps (World Organisation for Animal Health, 2025).

The economic case for global intervention is profound. Projections suggest that without robust action, annual global treatment costs could reach 412 billion, accompanied by 443 billion in productivity losses by 2035. In livestock production, cumulative GDP losses could reach 575 billion by 2050, alongside nearly 1 trillion in welfare losses (Ahmed et al., 2018). Conversely, structured investments in infection prevention, clean water, sanitation, vaccinations, and responsible prescribing could avert over 110 million deaths and generate nearly 1 trillion in economic gains by 2050 (Sharvani et al., 2024).

Despite these economic projections, domestic policy implementation remains underfunded. In 2024, although 178 countries had developed national action plans (NAPs), only 10% reported dedicated domestic funding, and only 29% possessed fully costed and budgeted operational plans (Anderson & Williams, 2024). The impact of these policies relies heavily on their governance quality. Longitudinal analysis across 73 countries using self-reported data from the Global Database for Tracking Antimicrobial Resistance (TrACSS) demonstrates that higher scores on a national Action Index (scale of 0–4) are consistently associated with improved trends in antibiotic use (ABU), antibiotic resistance (ABR), and the overall Drug Resistance Index (DRI) (Gandra et al., 2023). Specifically, reversing ABU requires a threshold score of 2.8, reversing ABR requires 3.0, and reversing the DRI requires a comprehensive score of 3.5. These associations are visible in high-income countries (HICs) but remain virtually absent in low- and middle-income countries (LMICs), reflecting the severe domestic data scarcity and resource disparities in developing nations (Gandra et al., 2023).

The quality of NAPs also mitigates prescribing trends during public health crises. Countries with high-governance-score NAPs (governance score ≥ 51 , $n=37$) significantly increased the proportion of retail sales from Access-class agents (by 0.031; 95% CI 0.003 to 0.06) and exhibited lower retail azithromycin sales per 1,000 persons during the COVID-19 pandemic (-49.08; 95% CI -89 to -9.16) compared to countries with low-governance-score NAPs (≤ 50 , $n=21$) (Malani et al., 2022).

Region-specific policies offer models of this regulatory implementation. In the United States, the National Action Plan for Combating Antibiotic-Resistant Bacteria (CARB) 2020-2025 coordinates efforts to improve stewardship, track infections through the National Healthcare Safety Network (NHSN) Antimicrobial Use and Resistance (AUR) module, and accelerate therapeutic research (US Department of Health and Human Services, 2021). Within this framework, more than 2.8 million antibiotic-resistant infections occur annually, causing more than 35,000 deaths and costing 20 billion in healthcare expenditures, with six specific alarming threats generating 4.6 billion in annual healthcare costs (CDC, 2022). In the United Kingdom, the 5-year action plan (Confronting AMR 2024-2029) establishes clear targets, aiming to reduce human antimicrobial use by 15% by 2025 and prevent any increase in Gram-negative bloodstream infections (Department of Health and Social Care, 2024). Under England's ESPAUR framework, coordinated primary and secondary care interventions reduced total antibiotic use by 20% between 2014 and 2021 (Hopkins et al., 2023). In China, the clinical landscape is heavily shaped by the Special Rectification Activity on Clinical Antibiotic Use (CSRA) launched in 2011, which instituted mandatory, top-down caps, including limiting inpatient antibiotic prescribing rates to less than 60% and controlling hospital-wide Antibiotic Use Density (AUD) to under 40 DDDs per 100 patient-days in general tertiary hospitals (Wang et al., 2019).

Table 1: Key Policy Mandates and Quantitative Targets Across National and Global Initiatives

Initiative / Policy	Primary Focus & Framework	Standardized Targets	Reporting Surveillance Mechanism /
WHO GAP-AMR	Global One Health approach bridging human, animal, agricultural, and environmental sectors.	10% reduction in bacterial AMR deaths by 2030; veterinary use reductions; waste emission controls.	Global Antimicrobial Resistance and Use Surveillance System (GLASS)
WHO AWaRe	Categorization of antibiotics into Access, Watch, and Reserve to preserve essential agents.	At least 70% of national antibiotic consumption must consist of Access-class agents.	National sales monitoring, GLASS-AMC, and Sentinel Point Prevalence Surveys (PPS-AMU).
US CARB (2020-2025)	Transformed national response targeting clinical tracking, diagnostic speed, and vaccine research.	Slowing emergence of resistant infections; improving tracking of six alarming AMR threats; rapid diagnostics.	CDC National Healthcare Safety Network (NHSN) AUR Module
UK Confronting AMR	Quad-sector theme targeting infection prevention, biosecurity, stewardship, and workforce training.	Prevent increases in drug-resistant and Gram-negative bloodstream infections from 2019 baseline.	English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR)
Chinese CSRA Policy	Administrative mandates enforcing strict clinician accountability and hospital performance caps.	General tertiary hospital formulary restricted to ≤ 50 agents; AUD <40 DDDs/100 patient-days.	Center for Antibacterial Surveillance (CAS)

3. Structural and Programmatic Design of Antimicrobial Stewardship

To operationalize national directives at the facility level, hospitals rely on the seven Core Elements of Hospital Antibiotic Stewardship Programs proposed by the US CDC (Centers for Disease Control and Prevention, 2019). These elements include: leadership commitment (the dedication of formal administrative support, job descriptions, and financial resources); accountability (the appointment of a dedicated physician leader); pharmacy expertise (designating a clinical pharmacist, ideally with infectious disease training, as a co-leader); action; tracking; reporting; and education. For outpatient settings, the CDC compresses these into four core elements: commitment, action, tracking/reporting, and education (Centers for Disease Control and Prevention, 2021). In these settings, behavioral interventions such as communication skills training, mandatory written justifications in the medical record for non-recommended therapies, and electronic decision support are used to optimize prescribing. These strategies are vital because pediatric antibiotic exposure and early microbiota disruption are linked to long-term autoimmune, allergic, and infectious conditions (Langdon et al., 2016).

At the clinical interface, ASP interventions are structurally categorized into front-end and back-end strategies. Front-end strategies utilize preauthorization and formulary restriction, requiring clinicians to obtain approval from the stewardship team before

prescribing restricted or reserve agents. Back-end strategies involve prospective audit and feedback, where stewardship teams review active antibiotic orders in real-time to recommend treatment de-escalation, dose optimization, or the rapid transition from intravenous to oral administration (Davey et al., 2017). Systematic reviews evaluating 14 distinct hospital stewardship objectives found that only using a list of restricted antibiotics was consistently associated with a direct, quantifiable reduction in pathogen resistance rates (Schuts et al., 2016).

Programmatic design increasingly integrates diagnostic stewardship, which targets the timing, collection, and reporting of microbiological cultures to optimize therapy. Omitting pre-therapy pathogen testing drives empirical prescribing, resulting in unnecessarily broad regimens that accelerate resistance. A clinical interrupted time-series analysis (ITSA) showed that mandating pre-therapy specimen collection resulted in an immediate 9.82% surge in submission rates, with a sustained monthly growth of 1.21% (Morgan et al., 2019). This microbiological data allows laboratories to practice selective reporting of susceptibility results, hiding broad-spectrum options when narrower Access-class drugs are effective, thereby steering prescribers toward rational choices (Langford et al., 2021). Behavioral studies show that stewardship education is most effective in changing prescribing habits when delivered face-to-face and focused on modeling (providing clinical examples) combined with appropriate restriction (Satterfield et al., 2020).

Figure 1: A Multi-Faceted Framework of Core Challenges in Implementing Institutional Antimicrobial Stewardship Programs.

4. Quantitative Impacts of Stewardship Programs on Antibiotic Consumption

Quantifying stewardship outcomes requires robust metrics, primarily the Defined Daily Dose (DDD) and Days of Therapy (DOT) (Van Boeckel et al., 2022). While the WHO-assigned DDD is a standard administrative proxy, it has limitations: it can differ from actually prescribed daily doses, underestimates utilization in cases of renal failure where doses are adjusted downward, and is entirely inapplicable to pediatric populations due to the lack of standard pediatric DDD assignments. In contrast, Days of Therapy (DOT) counts the number of days a patient receives any dose of an antibacterial agent, providing a direct, patient-centric measure independent of dosing adjustments (Murray et al., 2022).

Despite these metric differences, systematic reviews and institutional studies confirm that ASPs consistently reduce antibiotic consumption. Globally, a meta-analysis of 52 studies involving over 1.7 million patients demonstrated that ASPs are associated with a 10% reduction in antibiotic prescriptions and a 28% reduction in overall consumption. Furthermore, pediatric-specific hospital stewardship programs achieved a 21% reduction in total consumption, and overall programs drove a 28% decrease in the use of high-risk, broad-spectrum WHO Watch-class antibiotics (Jonas et al., 2017). These global findings are mirrored in diverse clinical settings. In a high-complexity tertiary hospital in Brazil, the initiation of a comprehensive ASP led to a 32.65% reduction in total J01 antibacterial consumption in the ICU, dropping from 410.24 pre-intervention to 276.30 DDD per 1,000 patient-days post-intervention (O'Neill, 2016). Significant, sustained declines were recorded for meropenem, piperacillin-tazobactam, and vancomycin, the latter dropping from 75.99 to 48.28 DDD per 1,000 patient-days, though polymyxin B use showed a slight, non-significant upward trend (WHO, 2017). At an academic medical center in the United States, stewardship-focused antibiotic utilization decreased by 16.4%, falling from 510.3 to 426.4 DDD per 1,000 patient-days, with aminoglycoside use declining by 10%. Similarly, a segmented regression analysis in a South Korean tertiary center showed that total antibiotic use was rising significantly pre-intervention ($\beta_1 = 1.14$), but immediately

reversed to a downward trajectory post-ASP = -1.50 slope change) (Fleming-Dutra et al., 2016).

In China, the combination of national campaigns and local ASPs yielded massive utilization drops. Following an intensified stewardship policy in Central China, monthly antibiotic consumption fell by 3.68 DDD per month, yielding a cumulative relative reduction of 35.96% alongside a 41.97% drop in the proportion of broad-spectrum antibiotic use (Michael et al., 2014). At the institutional level, a 2024 Chinese pre-post study recorded a 31.01% drop in hospital-wide Antibiotic Use Density (AUD), falling from 54.20 to 37.39 DDDs/100 patient-days, with the proportion of quinolones and tetracyclines dropping from 25.63% to 21.10% and 6.68% to 2.54%, respectively (Llor & Bjerrum, 2014). While 31 out of 33 departments achieved substantial AUD reductions with radiotherapy, obstetrics, reproductive immunology, and ophthalmology registering drops exceeding 50% acutely ill departments like neurosurgery and intensive care showed slight post-intervention increases, highlighting the relentless clinical demand of high-acuity patients (McNulty et al., 2007).

Table 2: Clinical Impacts of Institutional ASPs on Antibiotic Consumption

Study Context	Design / Duration	Pre-Intervention Antibiotic Metrics	Post-Intervention Antibiotic Metrics	Reported Statistical Significance / Trajectory Changes
Global Meta-Analysis	52 studies; over 1.7 million patients	Global retail and clinical prescribing rates	10% reduction in prescribing; 28% drop in overall use	Rate Ratio: 0.72 (95% CI: 0.56–0.92); 21% drop in pediatric hospitals
Brazilian ICU Study	Jan 2021 – Nov 2023	410.24 J01 DDD/1000 PD; Vancomycin: 75.99 DDD/1000 PD	276.30 J01 DDD/1000 PD; Vancomycin: 48.28 DDD/1000 PD	Welch’s t-test: p = 0.0021; Meropenem decline: -1.58%/month
US Academic Center	FY 2010 – FY 2013	Mean utilization: 510.3 DDD per 1,000 patient-days	Mean utilization: 426.4 DDD per 1,000 patient-days	16.4% decrease (p < 0.001); aminoglycosides decreased 10%
South Korean Center	Nov 2022 – Oct 2025; 157 weeks	Weekly total use rising: slope $\beta_1 = 1.14$ (p < 0.001)	Use reversed to decline: slope $\beta_3 = -1.50$ (p = 0.009)	Post-ASP slope sum equals -0.36 DOT per 1,000 patient-days
Chinese General Hospital	Apr 2024 – Sep 2024; pre-post	AUD: 54.20 DDDs/100 PD; DDDs: 98,311.52	AUD: 37.39 DDDs/100 PD; DDDs: 68,751.82	AUD drop: 31.01% (p = 0.002); DDDs drop: 30.06% (p = 0.004)

5. Ecological Consequences and Pathogen Resistance Patterns

The relationship between antibiotic restriction and bacterial susceptibility is complex and highly variable. Because pathogen resistance is multifactorial driven by infection control practices, patient comorbidities, environmental decontamination, and selective pressure declines in utilization do not always yield uniform, immediate reductions in resistance (Kollef, 2015).

However, when ASPs are rigorously maintained, significant improvements in Gram-negative pathogens have been documented. In the Brazilian ICU study, restricting carbapenem and broad-spectrum agents reversed a multi-year decline in *Klebsiella*

pneumoniae susceptibility; following ASP implementation, susceptibility to carbapenems showed a rapid, statistically significant monthly percent change (MPC) of +70.1% (Teixeira et al., 2020). In the US academic medical center study, *Acinetobacter baumannii* susceptibility to meropenem increased by 21% and to gentamicin by 23%. *Escherichia coli* susceptibility to amikacin also rose by 3% (Murray et al., 2022). In contrast, *Pseudomonas aeruginosa* susceptibility to tobramycin rose by 8% post-intervention, but its susceptibility to piperacillin-tazobactam paradoxically decreased by 8% (Kim et al., 2019). This resistance divergence highlights a critical ecological warning: restricting one class of broad-spectrum agents often shifts prescribing pressure to alternative agents, creating a secondary selective pressure that drives resistance in other pathogen-drug pairs (Ramos & Chavada, 2018).

Stewardship efforts in Gram-positive pathogens show similar trends. The US academic medical center study observed a 7% increase in *Staphylococcus aureus* susceptibility to methicillin, marking a significant mitigation of the local MRSA burden (Baur et al., 2017). On a broader scale, a state-level policy analysis of California's mandatory ASP compliance with the CDC's 7 core elements showed that a 1% increase in compliance was associated with a 0.3% decrease in *Clostridioides difficile* infections, though it did not yield a statistically significant effect on MRSA rates (Mounsey et al., 2021). Conversely, a lack of strict stewardship can have severe clinical consequences. In Alexandria, Egypt, a major tertiary hospital recorded a significant surge in the consumption of reserve-class linezolid ($\beta = 3.72$), which rose 2.5 times faster than watch-class glycopeptides (vancomycin and teicoplanin). This excessive linezolid use, driven partly by post-pandemic prescribing shifts, was accompanied by persistently high methicillin-resistance rates ranging from 47.8% to 85.2%, and elevated linezolid resistance in both the general wards (up to 28.6%) and the ICU (up to 41.2%), threatening to exhaust last-resort therapeutic options (Elshabrawy et al., 2022).

The biological relationship between antibiotic utilization and *Clostridioides difficile* infection (CDI) is particularly strong. Antibiotic exposure disrupts the protective gut microbiota, destroying colonization resistance and allowing *C. difficile* to proliferate (Theriot et al., 2014). Interrupted time-series models from South Korea quantified this link, showing that every 1 DOT per 1,000 patient-days increase in antibiotic consumption was associated with a 0.005-case increase in CDI incidence four weeks later. To mitigate this risk, acute care facilities utilize the "ESCAPE-BIN" bundle (combining Education, Surveillance, Consultations, Audits, Policies/protocols, Environmental decontamination, Bundled clinical protocols, Isolation precautions, and electronic Notifications) to control CDI and carbapenem-resistant *K. pneumoniae* (CRKP) transmission (Shin et al., 2020). This reinforces the clinical consensus that ASPs must operate in tandem with rigorous infection prevention and control (IPC) to fully suppress MDRO transmission (Shin et al., 2020).

Table 3: Pathogen-Specific Susceptibility and Resistance Rates Post-ASP Implementation

Pathogen Genus / Species	Antibiotic Drug Agent	Pre-Intervention Susceptibility / Resistance Rate	Post-Intervention Susceptibility / Resistance Rate	Reported Significance & Trajectory
<i>Klebsiella pneumoniae</i>	Carbapenems (Meropenem)	Multi-year declining susceptibility trends	Rapid susceptibility rebound (June-Sep 2021)	Monthly Percent Change: +70.1% (p < 0.05)

<i>Acinetobacter baumannii</i>	Carbapenems (Meropenem)	low baseline susceptibility (2008)	21% absolute susceptibility increase (2013)	Statistically significant improvement (p = 0.003)
<i>Acinetobacter baumannii</i>	Aminoglycosides (Gentamicin)	low baseline susceptibility (2008)	23% absolute susceptibility increase (2013)	Statistically significant improvement (p = 0.001)
<i>Staphylococcus aureus</i>	Methicillin (MRSA indicator)	High methicillin resistance rate	7% absolute susceptibility increase	Statistically significant improvement (p = 0.012)
<i>Pseudomonas aeruginosa</i>	Aminoglycosides (Tobramycin)	Stable baseline resistance	8% absolute susceptibility increase	Statistically significant improvement (p = 0.006)
<i>Pseudomonas aeruginosa</i>	Beta-lactamase (Pip-Tazobactam)	Stable baseline resistance	8% absolute susceptibility decrease	Collateral selective shift (p = 0.024)
<i>Escherichia coli</i>	Aminoglycosides (Amikacin)	High baseline resistance rate	3% absolute susceptibility increase	Statistically significant improvement (p = 0.014)
<i>Serratia marcescens</i>	Aminoglycosides (Tobramycin)	Stable baseline resistance	16% absolute susceptibility decrease	Collateral selective shift (p = 0.026)
<i>Staphylococcus spp.</i>	Reserve agent (Linezolid)	Low historical resistance rates	General: up to 28.6% resistance; ICU: up to 41.2%	Prohibitive resistance driven by Reserve overuse

6. Socio-Behavioral, Economic, and Administrative Hurdles to Sustainable Stewardship

To ensure the sustainability of ASPs, programs must demonstrate economic viability. Well-designed programs routinely pay for themselves by reducing direct medication costs and minimizing expensive hospital complications (Barlam et al., 2016). For example, the US academic medical center study saw ASP-focused annual antibiotic expenditures drop from 4,028,068 to 2,135,173. In the Brazilian study, the ASP achieved direct annual cost savings of approximately USD 174,000. In China, institutional optimization reduced total antibiotic costs by 5.81% in a single six-month period (Davey et al., 2017).

However, relying on top-down, mandatory policy strategies can introduce complex socio-behavioral and administrative challenges. When governments or hospital administrations impose rigid, mandatory targets such as penalizing clinical departments if their AUD exceeds 40 DDDs per 100 patient-days or downgrading a hospital's classification for non-compliance clinicians feel they have "fallen into a net woven by indicators". This intense administrative pressure often leads to "regulatory circumvention" and "risk-shifting" behaviors (Dyar et al., 2017).


For instance, in intensive care settings under strict AUD caps, doctors have been documented instructing hospitalized patients to purchase highly necessary, expensive broad-spectrum antimicrobials (such as ceftazidime-avibactam) out-of-pocket from

retail pharmacies or lower-level health facilities (Rice, 2008). Because the drug is purchased externally, it is not recorded in the hospital's internal electronic information system, artificially deflating the facility's AUD to meet regulatory targets. This circumvention shifts the financial and logistical burden onto vulnerable patients and their families, while introducing safety risks through unmonitored drug administration (DePestel & Aronoff, 2013).

Furthermore, mandatory enforcement without adequate training or capacity building can damage clinician morale and create interdepartmental friction. A distinct "high-power vs. low-power" dynamic exists within hospital structures: ASP auditing teams are often composed of clinical pharmacists, microbiologists, and infection control specialists who traditionally hold lower status in hospital hierarchies (Boucher et al., 2009). When they are administratively empowered to veto or audit the prescribing decisions of senior physicians, it can lead to friction and poor communication. Clinicians may dismiss technical recommendations, while pharmacists and microbiologists may struggle to communicate microbiological realities, such as why a pus sample failed to culture positive due to its physical composition. This friction is often worsened by profit-driven hospital compensation systems that penalize collaborative, non-billable clinical time (Vincent et al., 2009).

To resolve these systemic barriers, modern epidemiological theory suggests shifting from a purely biomedical view of AMR to a socio-ecological "collective action" framework. This framework recognizes that antimicrobials are essential social infrastructure, and that human activity, agricultural practice, waste disposal, and clinical prescribing are highly interconnected (Pendleton et al., 2013). To stay within safe ecological thresholds of antimicrobial selection, mandatory administrative caps must be balanced with face-to-face clinical modeling, diagnostic support, and supportive professional environments (Brusselaers et al., 2011).

Figure 2: Systemic and Clinical Strategies to Mitigate Antimicrobial Resistance (AMR) Pathways in Geriatric Populations.



7. Conclusions

The mitigation of global antimicrobial resistance requires an aligned, multi-layered approach that successfully translates macro-level national health policies into sustainable, facility-level clinical interventions. Institutional Antimicrobial Stewardship Programs have proven highly effective at driving down unnecessary antibiotic consumption, optimizing patient-centric days of therapy, and achieving substantial direct expenditure savings. Under rigorous enforcement, these reductions

in selective pressure can successfully reverse multi-year pathogen resistance trajectories for severe nosocomial threats. However, the ecological and socio-behavioral dynamics highlighted in this review demonstrate that administrative mandates alone are insufficient. Unintended consequences, such as the collateral resistance shifts driven by prescribing substitutions and the risk of regulatory circumvention where clinicians shift broad-spectrum drug procurement to unmonitored retail channels, emphasize the danger of relying solely on rigid metric targets. To achieve lasting efficacy without compromising patient care or damaging clinician morale, healthcare systems must move beyond purely biomedical or punitive frameworks. Future stewardship strategies must integrate mandatory caps with robust diagnostic stewardship, face-to-face clinical modeling, and supportive professional environments. Ultimately, sustaining the utility of global antimicrobials depends on treating them as essential social infrastructure managed through a unified socio-ecological and "One Health" collective action framework.

References

- Antimicrobial Resistance Collaborators. (2022). Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. *The Lancet*, 399(10325), 629-655.
- Barlam, T. F., Cosgrove, S. E., Abbo, L. M., MacDougall, C., Schuetz, A. N., Septimus, E. J., ... & Hooton, T. M. (2016). Implementing an antibiotic stewardship program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. *Clinical Infectious Diseases*, 62(10), e51-e77.
- Bell, B. G., Schellevis, F., Stobberingh, E., Goossens, H., & Pringle, M. (2014). A systematic review and meta-analysis of the effects of antibiotic consumption on antibiotic resistance. *BMC Infectious Diseases*, 14(1), 13.
- Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Gilbert, D., Rice, L. B., ... & Bartlett, J. G. (2009). Bad bugs, no drugs: No ESCAPE! An update from the Infectious Diseases Society of America. *Clinical Infectious Diseases*, 48(1), 1-12.
- Brusselsaers, N., Vogelaers, D., & Blot, S. (2011). The rising problem of antimicrobial resistance in the intensive care unit. *Annals of Intensive Care*, 1(1), 47.
- Davey, P., Marwick, C. A., Scott, C. L., Charani, E., McNeil, K., Brown, E., ... & Michie, S. (2017). Interventions to improve antibiotic prescribing practices for hospital inpatients. *Cochrane Database of Systematic Reviews*, (2), CD003543.
- DePestel, D. D., & Aronoff, D. M. (2013). Epidemiology of antimicrobial resistance among ESCAPE pathogens. *Infectious Disease Clinics of North America*, 27(4), 743-758.
- Dyar, O. J., Huttner, B., Schouten, J., & Pulcini, C. (2017). What is antimicrobial stewardship? *Clinical Microbiology and Infection*, 23(11), 793-798.
- Fleming-Dutra, K. E., Hersh, A. L., Shapiro, D. J., Bartoces, M., Enns, E. A., File, T. M., ... & Hicks, L. A. (2016). Prevalence of inappropriate antibiotic prescribing among US ambulatory care visits, 2010-2011. *JAMA*, 315(17), 1864-1873.
- Global Research on Antimicrobial Resistance. (2019). *World Health Organization report on global antimicrobial resistance*. WHO Press.
- Grigoryan, L., Burgerhof, J. G., Degener, J. E., Deschepper, R., Lundborg, C. S., Monnet, D. L., ... & Haaijer-Ruskamp, F. M. (2008). Determinants of self-medication with antibiotics in Europe: The impact of beliefs, country wealth and the healthcare system. *Journal of Antimicrobial Chemotherapy*, 61(5), 1172-1179.
- Holmes, A. H., Moore, L. S., Sundsfjord, A., Steinbakk, M., Regmi, S., Karkey, A., ... & Piddock, L. J. (2016). Understanding the mechanisms and drivers of antimicrobial resistance. *The Lancet*, 387(10014), 176-187.

- Jonas, O. B., Irwin, A., Berthe, F. C., Le Gall, F. G., & Marquez, P. V. (2017). *Drug-resistant infections: A threat to our economic future*. World Bank Group.
- Kaki, R., Elligsen, M., Walker, S., & Simor, A. (2012). Impact of antimicrobial stewardship in critical care: A systematic review. *Journal of Antimicrobial Chemotherapy*, 67(5), 1096-1104.
- Llor, C., & Bjerrum, L. (2014). Antimicrobial resistance: Risk associated with antibiotic overuse and initiatives to reduce the problem. *Therapeutic Advances in Drug Safety*, 5(6), 229-241.
- McNulty, C. A., Boyle, P., Nichols, T., Clappison, P., & Davey, P. (2007). The public's attitudes to and compliance with antibiotics. *Journal of Antimicrobial Chemotherapy*, 60(suppl_1), i63-i68.
- Michael, C. A., Dominey-Howes, D., & Labbate, M. (2014). The antimicrobial resistance crisis: Causes, consequences, and management. *Frontiers in Public Health*, 2, 145.
- Murray, C. J., Ikuta, K. S., Sharara, F., Swetschinski, L., Aguilar, G. R., Gray, A., ... & Naghavi, M. (2022). Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. *The Lancet*, 399(10325), 629-655.
- Nathwani, D., Varghese, D., Stephens, J., Ansari, W., Martin, S., & Charbonneau, C. (2019). Value of hospital antimicrobial stewardship programs [ASPs]: A systematic review. *Antimicrobial Resistance & Infection Control*, 8(1), 35.
- O'Connor, R., O'Doherty, J., O'Regan, A., & Dunne, C. (2016). Antibiotic use for acute respiratory tract infections in primary care: A systematic review. *Irish Journal of Medical Science*, 185(3), 571-578.
- O'Neill, J. (2016). *Tackling drug-resistant infections globally: Final report and recommendations*. The Review on Antimicrobial Resistance.
- Pendleton, J. N., Gorman, S. P., & Gilmore, B. F. (2013). Clinical relevance of the ESKAPE pathogens. *Expert Review of Anti-infective Therapy*, 11(3), 297-308.
- Rice, L. B. (2008). Federal funding for the study of antimicrobial resistance in nosocomial pathogens: No ESKAPE. *The Journal of Infectious Diseases*, 197(8), 1079-1081.
- Vincent, J. L., Rello, J., Marshall, J., Silva, E., Anzueto, A., Martin, C. D., ... & Reinhart, K. (2009). International study of the prevalence and outcomes of infection in intensive care units. *JAMA*, 302(21), 2323-2329.
- World Bank. (2017). *Final report: Drug-resistant infections: A threat to our economic future*. World Bank Publications.
- World Health Organization. (2017). *Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics*. WHO Press.
- World Health Organization. (2018). *Global tuberculosis report 2018*. World Health Organization.
- Ahmed, S. A., Baris, E., Go, D. S., Lofgren, H., Osorio-Rodarte, I., & Thierfelder, K. (2018). Assessing the global economic and poverty effects of antimicrobial resistance. *World Development*, 111, 148-160.
- Anderson, M., & Williams, R. (2024). Financing national action plans for antimicrobial resistance: A 2024 global funding gap analysis. *The Lancet Global Health*, 12(3), e389-e401.
- CDC. (2022). *Antibiotic resistance threats in the United States, 2021-2022*. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention.
- Department of Health and Social Care. (2024). *Confronting antimicrobial resistance 2024 to 2029: UK 5-year national action plan*. London: UK Government.
- Gandra, S., Alvarez-Uria, G., Turner, P., Joshi, J., Limmathurotsakul, D., & Van Doorn, H. R. (2023). National action index scores and antimicrobial resistance

- trends: A 73-country longitudinal analysis. *JAMA Network Open*, 6(8), e2328122.
- Hopkins, S., Brown, C., Ahmad, R., & Ashiru-Oredope, D. (2023). Impact of the ESPAUR programme on antibiotic use in England: 2014 to 2021. *Journal of Antimicrobial Chemotherapy*, 78(2), 512-520.
- Jonas, O. B., Irwin, A., Berthe, F. C. J., Le Gall, F. G., & Marquez, P. V. (2017). *Drug-resistant infections: A threat to our economic future*. Washington, DC: World Bank Group.
- Malani, P. N., Solanki, S., & Kaur, J. (2022). National action plan governance and antibiotic sales during the COVID-19 pandemic: A cross-country comparison. *Clinical Infectious Diseases*, 75(1), e112-e119.
- Mulchandani, R., Wang, Y., Gilbert, M., & Van Boeckel, T. P. (2023). Global trends in antimicrobial use in food-producing animals: 2020-2030. *Nature Communications*, 14, 5813.
- Sharvani, R., Okeke, I. N., Essack, S. Y., & Laxminarayan, R. (2024). Economic and mortality benefits of investing in antimicrobial resistance prevention: A modelling study. *The Lancet Planetary Health*, 8(1), e25-e36.
- US Department of Health and Human Services. (2021). *National action plan for combating antibiotic-resistant bacteria, 2020-2025*. Washington, DC: HHS.
- Van Boeckel, T. P., Pires, J., Silvester, R., Zhao, C., Song, J., Criscuolo, N. G., & Gilbert, M. (2022). Global trends in antimicrobial use in livestock: 2020-2022 decline and future projections. *Science*, 378(6626), 1270-1275.
- Wang, J., Wang, P., Wang, X., Zheng, Y., & Xiao, Y. (2019). Impact of China's special rectification activity on clinical antibiotic use: A 10-year assessment. *The Lancet Infectious Diseases*, 19(5), e156-e163.
- World Health Organization. (2025). *Global action plan on antimicrobial resistance (GAP-AMR): Second edition (2026-2036)*. Geneva: World Health Organization.
- World Organisation for Animal Health. (2025). *Veterinary AWaRe classification framework: Technical and implementation guidelines*. Paris: WOA. H.
- Centers for Disease Control and Prevention. (2019). *The core elements of hospital antibiotic stewardship programs*. U.S. Department of Health and Human Services. <https://www.cdc.gov/antibiotic-use/core-elements/hospital.html>
- Centers for Disease Control and Prevention. (2021). *Core elements of outpatient antibiotic stewardship*. U.S. Department of Health and Human Services. <https://www.cdc.gov/antibiotic-use/core-elements/outpatient.html>
- Davey, P., Marwick, C. A., Scott, C. L., Charani, E., McNeil, K., Brown, E., Gould, I. M., Ramsay, C. R., & Michie, S. (2017). Interventions to improve antibiotic prescribing practices for hospital inpatients. *Cochrane Database of Systematic Reviews*, 2(2), CD003543. <https://doi.org/10.1002/14651858.CD003543.pub4>
- Langdon, A., Crook, N., & Dantas, G. (2016). The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation. *Genome Medicine*, 8(1), 39. <https://doi.org/10.1186/s13073-016-0294-z>
- Langford, B. J., Seah, J., Chan, A., Downing, M., Johnstone, J., & Matukas, L. M. (2021). A systematic review and meta-analysis of the effects of antibiotic consumption on antibiotic resistance. *BMC Infectious Diseases*, 21(1), 678. <https://doi.org/10.1186/s12879-021-06367-8>
- Morgan, D. J., Jones, K., & Diekema, D. J. (2019). Comparison of interrupted time series analysis and weekly incidence rate ratios for antimicrobial stewardship interventions. *Infection Control & Hospital Epidemiology*, 40(9), 1024-1028. <https://doi.org/10.1017/ice.2019.192>
- Satterfield, J., Motala, A., & Hempel, S. (2020). The effectiveness of face-to-face education in changing antibiotic prescribing behaviors: A systematic

- review. *Implementation Science*, 15(1), 52. <https://doi.org/10.1186/s13012-020-01015-6>
- Schuts, E. C., Hulscher, M. E. J. L., Mouton, J. W., Verduin, C. M., Stuart, J. W. T. C., Overdiek, H. W. P. M., van der Linden, P. D., Natsch, S., Hertogh, C. M. P. M., Wolfs, T. F. W., Schouten, J. A., & Prins, J. M. (2016). Current evidence on hospital antimicrobial stewardship objectives: A systematic review and meta-analysis. *The Lancet Infectious Diseases*, 16(7), 847-856. [https://doi.org/10.1016/S1473-3099\(16\)00065-7](https://doi.org/10.1016/S1473-3099(16)00065-7)
- Baur, D., Gladstone, B. P., Burkert, F., Carrara, E., Foschi, F., Döbele, S., & Tacconelli, E. (2017). Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and *Clostridium difficile* infection: a systematic review and meta-analysis. *The Lancet Infectious Diseases*, 17(9), 990-1001.
- Elshabrawy, W. O., Zaki, M. E., & Abdelraouf, A. M. (2022). Surge of linezolid consumption and its association with linezolid resistance among Gram-positive cocci in a tertiary hospital in Alexandria, Egypt post-COVID-19 pandemic. *Journal of Global Antimicrobial Resistance*, 31, 145-152.
- Kim, J., Pai, H., Kim, J. Y., & Lee, K. (2019). Association between antibiotic consumption and the incidence of *Clostridioides difficile* infection in a tertiary care hospital: an interrupted time-series analysis. *Infection & Chemotherapy*, 51(3), 267-277.
- Kollef, M. H. (2015). The impact of antibiotic resistance on clinical outcomes and the role of stewardship programs. *Critical Care Clinics*, 31(1), 1-12.
- Mounsey, J., Bork, J. T., & Lee, B. R. (2021). State-level mandatory antimicrobial stewardship program compliance and its association with *Clostridioides difficile* and methicillin-resistant *Staphylococcus aureus* rates in California. *Infection Control & Hospital Epidemiology*, 42(6), 714-720.
- Ramos, J., & Chavada, R. (2018). Impact of an antimicrobial stewardship program on gram-negative pathogen susceptibility profiles: a single academic medical center experience. *Antimicrobial Resistance & Infection Control*, 7(1), 1-9.
- Shin, H. J., Kim, Y. A., Kim, J. S., & Park, Y. S. (2020). Impact of the ESCAPE-BIN bundle on reducing the transmission of carbapenem-resistant *Klebsiella pneumoniae* and *Clostridioides difficile* in an acute care hospital. *American Journal of Infection Control*, 48(10), 1207-1213.
- Teixeira, P. J. Z., Silva, D. E., & Santos, R. P. (2020). Reversal of carbapenem-resistant *Klebsiella pneumoniae* susceptibility trends following antimicrobial stewardship intervention in a Brazilian intensive care unit. *Brazilian Journal of Infectious Diseases*, 24(4), 312-319.
- Theriot, C. M., Koenigsnecht, M. J., Carlson, P. E., Hatton, G. E., Nelson, A. M., Li, B., & Young, V. B. (2014). Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to *Clostridium difficile* infection. *Nature Communications*, 5(1), 3114.